En-bloc rectosigmoid and mesorectum resection as part of pelvic cytoreductive surgery in advanced ovarian cancer

Ovarian cancer surgery rectosigmoid

Journal

Journal of the Turkish German Gynecological Association
ISSN: 1309-0399
Titre abrégé: J Turk Ger Gynecol Assoc
Pays: Turkey
ID NLM: 101272522

Informations de publication

Date de publication:
03 09 2020
Historique:
entrez: 14 1 2020
pubmed: 14 1 2020
medline: 14 1 2020
Statut: ppublish

Résumé

“En-bloc” resection of pelvic tumor in ovarian cancer (OC) is still controversial. The aim was to analyze results in an OC series from a single center, all of whom underwent “en-bloc” resection as part of cytoreductive surgery. Clinical and surgical records from sixty patients with ovarian carcinoma who underwent “en-bloc” resection surgery were retrospectively analyzed. Patients’ mean age was 56 years; 36 patients had primary disease and 24 had recurrent disease. Carcinomatosis was present in 46.7% of patients. Primary surgery was performed in 49 and interval debulking surgery in eleven. Complete cytoreduction was achieved in 55.0% and optimal in 38.3% of patients. Carcinomatosis significantly decreased the probability of complete cytoreduction [odds ratio (OR): 0.22; p=0.021]. Mesorectal infiltration occurred in 83% of patients. Risk of death was non-significantly higher (hazard ratio: 1.9) in women with mesorectal infiltration. Median overall survival was longer for patients without infiltration (46.1 vs 79.1 months; p=0.15). Eighty-five percent suffered from mild to moderate complications and colorectal anastomosis (CRA) leak occurred in two patients (3.6%) with CRA below 6 cm. Diaphragm resection had >5 times the risk for major complications (OR: 5.35; p=0.014). There was no three month mortality. When contiguous gross extension of disease to pelvic peritoneum and sigmoid colon is found, in patients with advanced OC, microscopic involvement of the mesorectum and intestinal wall is present in most cases making “en-bloc” resection necessary if complete cytoreduction is to be achieved. The associated morbidity is acceptable.

Identifiants

pubmed: 31927810
doi: 10.4274/jtgga.galenos.2019.2019.0128
pmc: PMC7495125
doi:

Types de publication

Journal Article

Langues

eng

Pagination

156-162

Références

Gynecol Oncol. 2005 Dec;99(3):608-14
pubmed: 16153697
Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007565
pubmed: 21833960
Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7
pubmed: 18060979
Gynecol Oncol. 1998 May;69(2):103-8
pubmed: 9600815
Eur J Surg Oncol. 2018 Jun;44(6):750-753
pubmed: 29580734
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008765
pubmed: 23450588
Gynecol Oncol. 2019 May;153(2):362-367
pubmed: 30846223
Am J Obstet Gynecol. 2000 Jun;182(6):1321-7
pubmed: 10871445
J Am Coll Surg. 2003 Oct;197(4):565-74
pubmed: 14522325
Gynecol Oncol. 2012 Aug;126(2):220-3
pubmed: 22555105
Gynecol Oncol. 2001 Oct;83(1):115-20
pubmed: 11585422
Int J Gynecol Cancer. 2013 Nov;23(9):1590-6
pubmed: 24172095
J Am Coll Surg. 2006 Oct;203(4):521-6
pubmed: 17000396
Gynecol Oncol. 1995 Nov;59(2):200-6
pubmed: 7590473
Clin Colorectal Cancer. 2016 Mar;15(1):82-90.e1
pubmed: 26372333
Gynecol Oncol. 2017 Apr;145(1):21-26
pubmed: 28159407
Gynecol Oncol. 2006 Dec;103(3):977-84
pubmed: 16837030
Gynecol Oncol. 2016 Aug;142(2):217-24
pubmed: 27261325
Am J Obstet Gynecol. 2006 Aug;195(2):585-9; discussion 589-90
pubmed: 16730631
Gynecol Oncol. 2019 May;153(2):238-241
pubmed: 30833135
Int J Gynecol Cancer. 2009 Jul;19(5):968-73
pubmed: 19574794
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Gynecol Oncol. 2013 Sep;130(3):493-8
pubmed: 23747291
Gynecol Oncol. 2019 Jun;153(3):549-554
pubmed: 30952369
Eur J Surg Oncol. 2011 Dec;37(12):1085-92
pubmed: 21945640
Gynecol Oncol. 2001 Dec;83(3):481-4
pubmed: 11733959
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Br J Surg. 2008 Jun;95(6):770-3
pubmed: 18418859
Int J Gynecol Cancer. 2018 Nov;28(9):1699-1705
pubmed: 30371561
Cancer. 2000 Jan 15;88(2):389-97
pubmed: 10640973

Auteurs

Juan Luis Alcazar (JL)

Clinic of Obstetrics and Gynecology, Clinica Universidad de Navarra, Pamplona, Spain

Matias Jurado (M)

Clinic of Obstetrics and Gynecology, Clinica Universidad de Navarra, Pamplona, Spain

Jose Angel Minguez (JA)

Clinic of Obstetrics and Gynecology, Clinica Universidad de Navarra, Pamplona, Spain

Enrique Chacon (E)

Clinic of Obstetrics and Gynecology, Clinica Universidad de Navarra, Pamplona, Spain

Fernando Martinez-Regueira (F)

Clinic of Surgery, Clinica Universidad de Navarra, Pamplona, Spain

Classifications MeSH